These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35918701)

  • 1. Current causes of death in familial hypercholesterolemia.
    Marco-Benedí V; Bea AM; Cenarro A; Jarauta E; Laclaustra M; Civeira F
    Lipids Health Dis; 2022 Aug; 21(1):64. PubMed ID: 35918701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers.
    Besseling J; Kindt I; Hof M; Kastelein JJ; Hutten BA; Hovingh GK
    Atherosclerosis; 2014 Mar; 233(1):219-23. PubMed ID: 24529147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maternally inherited hypercholesterolemia does not modify the cardiovascular phenotype in familial hypercholesterolemia.
    Marco-Benedí V; Laclaustra M; Bea AM; Suarez-Tembra M; Plana N; Pinto X; Brea A; Sanchez-Hernandez RM; Civeira F
    Atherosclerosis; 2021 Mar; 320():47-52. PubMed ID: 33529866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular disease prevention in heterozygous familial hypercholesterolemia: how important is a healthy diet in the era of long-lasting cholesterol-lowering drug therapies?
    Roy G; Drouin-Chartier JP
    Curr Opin Lipidol; 2024 Feb; 35(1):1-6. PubMed ID: 37910156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy.
    Glueck CJ; Shah P; Goldenberg N; Prince M; Lee K; Jetty V; Kumar A; Goldenberg M; Wang P
    Lipids Health Dis; 2016 Mar; 15():55. PubMed ID: 26968977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of the Definition of Severe Familial Hypercholesterolemia for Stratification of Heterozygous Patients.
    Pérez-Calahorra S; Sánchez-Hernández RM; Plana N; Marco-Benedi V; Pedro-Botet J; Almagro F; Brea A; Ascaso JF; Lahoz C; Civeira F;
    Am J Cardiol; 2017 Mar; 119(5):742-748. PubMed ID: 28081939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unveiling Familial Hypercholesterolemia-Review, Cardiovascular Complications, Lipid-Lowering Treatment and Its Efficacy.
    Fularski P; Hajdys J; Majchrowicz G; Stabrawa M; Młynarska E; Rysz J; Franczyk B
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy.
    Vishwanath R; Hemphill LC
    J Clin Lipidol; 2014; 8(1):18-28. PubMed ID: 24528684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.
    Jetty V; Glueck CJ; Lee K; Goldenberg N; Prince M; Kumar A; Goldenberg M; Anand I; Wang P
    Vasc Health Risk Manag; 2017; 13():247-253. PubMed ID: 28740397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
    Arca M
    Atherosclerosis; 2017 Jan; 256():134-145. PubMed ID: 27993383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial hypercholesterolemia/autosomal dominant hypercholesterolemia: Molecular defects, the LDL-C continuum, and gradients of phenotypic severity.
    Foody JM; Vishwanath R
    J Clin Lipidol; 2016; 10(4):970-986. PubMed ID: 27578130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How Can We Identify Very High-Risk Heterozygous Familial Hypercholesterolemia?
    Kataoka Y; Funabashi S; Doi T; Harada-Shiba M
    J Atheroscler Thromb; 2022 Jun; 29(6):795-807. PubMed ID: 35022364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in phenotype, genotype and cardiovascular events between patients with probable and definite heterozygous familial hypercholesterolemia.
    Cao YX; Zhou BY; Sun D; Li S; Guo YL; Zhu CG; Wu NQ; Gao Y; Xu RX; Liu G; Dong Q; Li JJ
    Per Med; 2019 Nov; 16(6):467-478. PubMed ID: 31691639
    [No Abstract]   [Full Text] [Related]  

  • 14. Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease.
    Yuan G; Wang J; Hegele RA
    CMAJ; 2006 Apr; 174(8):1124-9. PubMed ID: 16606962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.
    Jensen HK
    Dan Med Bull; 2002 Nov; 49(4):318-45. PubMed ID: 12553167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of lipid-lowering treatment in cardiovascular disease prevalence in familial hypercholesterolemia.
    Perez-Calahorra S; Laclaustra M; Marco-Benedí V; Lamiquiz-Moneo I; Pedro-Botet J; Plana N; Sanchez-Hernandez RM; Amor AJ; Almagro F; Fuentes F; Suarez-Tembra M; Civeira F;
    Atherosclerosis; 2019 May; 284():245-252. PubMed ID: 30827715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and genetic differences between heterozygous familial hypercholesterolemia patients with and without type 2 diabetes.
    Climent E; Pérez-Calahorra S; Benaiges D; Pintó X; Suárez-Tembra M; Plana N; Sánchez-Hernández RM; Valdivielso P; Ascaso JF; Pedro-Botet J
    Rev Esp Cardiol (Engl Ed); 2020 Sep; 73(9):718-724. PubMed ID: 31672559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C.
    van Delden XM; Huijgen R; Wolmarans KH; Brice BC; Barron JK; Blom DJ; Marais AD
    Atherosclerosis; 2018 Oct; 277():327-333. PubMed ID: 30270067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.
    Lambert G; Petrides F; Chatelais M; Blom DJ; Choque B; Tabet F; Wong G; Rye KA; Hooper AJ; Burnett JR; Barter PJ; Marais AD
    J Am Coll Cardiol; 2014 Jun; 63(22):2365-73. PubMed ID: 24632287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
    McCullough PA; Ballantyne CM; Sanganalmath SK; Langslet G; Baum SJ; Shah PK; Koren A; Mandel J; Davidson MH
    Am J Cardiol; 2018 Apr; 121(8):940-948. PubMed ID: 29472008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.